Veritable’s AbbVie ABBV Stock Holding History

Veritable’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-115,021	Closed	-$15.5M	–	3
2023 Q2	$15.5M	Buy	115,021 +624	+0.5%	+$91.5K	0.24%	44
2023 Q1	$18.2M	Sell	114,397 -10,531	-8%	-$1.61M	0.3%	40
2022 Q4	$20.2M	Buy	124,928 +1,016	+0.8%	+$156K	0.35%	33
2022 Q3	$16.6M	Sell	123,912 -33,266	-21%	-$4.77M	0.32%	38
2022 Q2	$24.1M	Buy	157,178 +43,856	+39%	+$6.7M	0.43%	26
2022 Q1	$18.4M	Sell	113,322 -3,072	-3%	-$446K	0.28%	39
2021 Q4	$15.8M	Buy	116,394 +3,450	+3%	+$408K	0.23%	55
2021 Q3	$12.2M	Buy	112,944 +1,020	+0.9%	+$117K	0.2%	62
2021 Q2	$12.6M	Sell	111,924 -7,428	-6%	-$837K	0.2%	61
2021 Q1	$12.9M	Buy	119,352 +2,465	+2%	+$264K	0.22%	55
2020 Q4	$12.5M	Sell	116,887 -2,239	-2%	-$215K	0.23%	54
2020 Q3	$10.4M	Sell	119,126 -448	-0.4%	-$42.2K	0.21%	63
2020 Q2	$11.7M	Buy	119,574 +9,965	+9%	+$877K	0.25%	53
2020 Q1	$8.35M	Sell	109,609 -3,027	-3%	-$258K	0.2%	68
2019 Q4	$9.97M	Sell	112,636 -1,026	-0.9%	-$85.2K	0.18%	78
2019 Q3	$8.61M	Sell	113,662 -1,383	-1%	-$94.8K	0.17%	83
2019 Q2	$8.37M	Buy	115,045 +1,365	+1%	+$107K	0.17%	82
2019 Q1	$9.16M	Sell	113,680 -383	-0.3%	-$31.3K	0.18%	80
2018 Q4	$10.5M	Sell	114,063 -772	-0.7%	-$67.9K	0.24%	60
2018 Q3	$10.9M	Buy	114,835 +3,934	+4%	+$373K	0.22%	68
2018 Q2	$10.3M	Sell	110,901 -1,291	-1%	-$126K	0.22%	63
2018 Q1	$10.6M	Sell	112,192 -2,212	-2%	-$243K	0.23%	62
2017 Q4	$11.1M	Sell	114,404 -19,991	-15%	-$1.88M	0.22%	61
2017 Q3	$11.9M	Sell	134,395 -2,413	-2%	-$184K	0.25%	58
2017 Q2	$9.92M	Buy	136,808 +766	+0.6%	+$51.5K	0.23%	72
2017 Q1	$8.86M	Sell	136,042 -1,396	-1%	-$87.8K	0.21%	78
2016 Q4	$8.61M	Buy	137,438 +2,167	+2%	+$132K	0.21%	76
2016 Q3	$8.53M	Buy	135,271 +2,189	+2%	+$142K	0.21%	71
2016 Q2	$8.24M	Buy	133,082 +43	+0%	+$2.62K	0.21%	74
2016 Q1	$7.6M	Buy	133,039 +124	+0.1%	+$6.91K	0.2%	77
2015 Q4	$7.87M	Buy	132,915 +1,644	+1%	+$94.7K	0.22%	70
2015 Q3	$7.14M	Buy	131,271 +678	+0.5%	+$44.1K	0.21%	74
2015 Q2	$8.78M	Sell	130,593 -24,111	-16%	-$1.57M	0.24%	67
2015 Q1	$9.06M	Sell	154,704 -603	-0.4%	-$36.4K	0.19%	90
2014 Q4	$10.2M	Sell	155,307 -563	-0.4%	-$35.5K	0.21%	84
2014 Q3	$9M	Buy	155,870 +6,083	+4%	+$338K	0.19%	91
2014 Q2	$8.45M	Sell	149,787 -12,011	-7%	-$630K	0.18%	93
2014 Q1	$8.32M	Buy	161,798 +769	+0.5%	+$38.9K	0.18%	94
2013 Q4	$8.5M	Sell	161,029 -834	-0.5%	-$41K	0.19%	93
2013 Q3	$7.24M	Buy	161,863 +4,739	+3%	+$210K	0.17%	102
2013 Q2	$6.5M	Buy	+157,124	New	+$6.87M	0.16%	109

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Veritable's ABBV Position: Q3 2023 in Review

Veritable sold out of AbbVie (ABBV) in Q3 2023, closing a stake of 115,021 shares — an estimated $15.5M sold.

Veritable first reported a position in ABBV in Q2 2013 and held it in 41 quarters. The position peaked at $24.1M in Q2 2022. 3,109 funds tracked by Wall St. Rank hold ABBV as of Q3 2023.

Veritable reported no remaining AbbVie position as of Q3 2023 after selling out during the quarter.
Veritable sold 115,021 AbbVie shares in Q3 2023, an estimated $15.5M.
Veritable first reported a position in AbbVie in Q2 2013 and held it in 41 quarters.
Veritable's AbbVie position peaked at $24.1M in Q2 2022.
3,109 funds tracked by Wall St. Rank held AbbVie as of Q3 2023.

Based on Veritable's 13F filing for Q3 2023.